Biotricity Inc. entered into exchange agreements with holders of 14,144,325 common shares, 3,992,427 options, and 1,436,216 warrants. These securities were exchanged for 1,957,297 shares of newly created Series C Preferred Stock at a ratio of 10:1. The Series C Preferred Stock carries 40 votes per share. The preferred stock will automatically convert into 59.6% of the company's common stock upon a Qualified Financing of at least $15 million. If no Qualified Financing occurs by March 31, 2028, holders have the right to convert each share into 10 shares of common stock.